rohitintel
Uploaded by
10 SLIDES
1 VIEWS
0LIKES

Adalimumab PPT

DESCRIPTION

The Adalimumab market is growing steadily due to the rising prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohnu2019s disease. Adalimumab, widely known under the brand Humira, is a tumor necrosis factor (TNF) inhibitor that works by reducing inflammation and slowing disease progression. The market is projected to expand from USD 148 million in 2025 to USD 195 million by 2034, at a CAGR of 4.9%. Growth is supported by increasing adoption of biologics, expanding biosimilar availability, and improving healthcare infrastructure, particularly across emerging markets.

1 / 10

Download Presentation

Adalimumab PPT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 01 LATEST RESEARCH REPORT Adalimumab Market Growth Analysis, Market Dynamics, Key Players, Innovations, Outlook, and Forecast (2026–2034) www.intelmarketresearch.com

  2. 02 MARKET OVERVIEW Adalimumab, marketed under the brand name Humira among others, is a biologic medication classified as a tumor necrosis factor (TNF) inhibitor. It is primarily prescribed for treating autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. The drug works by targeting and neutralizing TNF-alpha, a key inflammatory protein involved in these conditions. CLICK FOR MORE DETAIL help@intelmarketresearch.com www.intelmarketresearch.com

  3. 03 Adalimumab Market (2026–2034) MARKET SIZE MARKET SIZE USD 148 million in 2025 USD 195 million in 2034 CAGR of 4.9% As the market continues to expand, ongoing innovations and shifting dynamics are expected to drive further progress and growth. www.intelmarketresearch.com help@intelmarketresearch.com

  4. MARKET SEGMENTATION OVERVIEW 04 By Application By Type • Rheumatoid Arthritis • Psoriatic Arthritis • Ankylosing Spondylitis • Branded Adalimumab (Humira) • Adalimumab Biosimilars By End User • Hospitals • Specialty Clinics • Retail Pharmacies www.intelmarketresearch.com help@intelmarketresearch.com

  5. 05 MARKET DYNAMICS Increasing Prevalence of Autoimmune Diseases The Adalimumab Market is primarily driven by the rising incidence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and Crohn's disease. With over 20 million cases reported globally, the demand for biologic treatments like adalimumab continues to surge. Its high efficacy in reducing inflammation and slowing disease progression positions it as a frontline therapy. www.intelmarketresearch.com help@intelmarketresearch.com

  6. 06 MARKET OPPORTUNITIES Asia-Pacific Market Expansion The APAC region represents the fastest-growing market for adalimumab, with an anticipated 12.7% growth rate through 2028. Improving healthcare infrastructure, rising autoimmune disease awareness, and increasing biosimilar penetration create significant expansion opportunities in this underpenetrated market. www.intelmarketresearch.com help@intelmarketresearch.com

  7. 07 Regional Analysis: Adalimumab Market The regional analysis offers a detailed view of market segmentation, with a focus on performance, opportunities, and emerging trends in various regions. EUROPE NORTH AMERICA Europe represents the second-largest Adalimumab market, characterized by unified regulatory oversight through EMA alongside country-specific reimbursement policies. Biosimilar adoption is particularly strong in Western Europe, driven by cost-containment measures. North American Adalimumab market dominates globally due to robust healthcare infrastructure and high adoption of biologic treatments. The region benefits from favorable reimbursement policies, extensive research activities, and strong presence of key manufacturers. www.intelmarketresearch.com help@intelmarketresearch.com

  8. n 08 Top 10 Companies Driving Growth in Adalimumab Market • Biogen Inc. • Alvotech (AVT02) • Amgevita (EU brand) • Pfizer Inc. (Abrilada) • Fresenius Kabi (Idacio) These companies are leading innovation and driving growth in the market. To explore the full list of top players and gain deeper insights, download the sample below. DOWNLOAD FREE SAMPLE PDF www.intelmarketresearch.com help@intelmarketresearch.com

  9. ABOUT US: 09 At Intel Market Research, we provide data-driven market intelligence that empowers businesses to navigate complex markets and make informed decisions. Our expert team combines cutting-edge analytics with deep industry knowledge to deliver actionable insights across sectors like technology, healthcare, finance, and manufacturing. www.intelmarketresearch.com help@intelmarketresearch.com

  10. 10 +91 9169164321 www.intelmarketresearch.com help@intelmarketresearch.com

More Related